Mostrar el registro sencillo del ítem

dc.contributor.authorTeruel Artacho, María
dc.contributor.authorBarturen Briñas, Guillermo
dc.contributor.authorMartínez Bueno, Manuel 
dc.contributor.authorCastellini Pérez, Olivia
dc.contributor.authorBarroso Gil, Miguel
dc.contributor.authorPovedano Espejo, Elena
dc.contributor.authorKerick, Martin
dc.contributor.authorMarañón Lizana, Concepción
dc.contributor.authorMartín Ibáñez, Javier
dc.contributor.authorCarnero Montoro, Elena
dc.contributor.authorAlarcón Riquelme, Marta Eugenia 
dc.contributor.authorCastro Villegas, Mª Carmen
dc.contributor.authorOrtego Centeno, Norberto 
dc.contributor.authorFernández Roldán, María Concepción
dc.contributor.authorRaya Álvarez, Enrique Germán 
dc.contributor.authorJiménez Moleón, Inmaculada
dc.contributor.authorRodríguez Maresca, Manuel
dc.contributor.authorLópez Berrio, Antonio
dc.contributor.authorAguilar Quesada, Rocío
dc.contributor.authorNavarro Linares, Héctor
dc.contributor.authorMuchmore, Brian
dc.contributor.authorPRECISESADS Clinical Consortium
dc.contributor.authorPRECISESADS Flow Cytometry Study Group
dc.date.accessioned2022-01-12T08:11:07Z
dc.date.available2022-01-12T08:11:07Z
dc.date.issued2021-12-02
dc.identifier.citationTeruel, M... [et al.]. Integrative epigenomics in Sjögren´s syndrome reveals novel pathways and a strong interaction between the HLA, autoantibodies and the interferon signature. Sci Rep 11, 23292 (2021). [https://doi.org/10.1038/s41598-021-01324-0]es_ES
dc.identifier.urihttp://hdl.handle.net/10481/72314
dc.descriptionFunding for the preparation of this manuscript has received support from the Innovative Medicines Initiative Joint Undertaking under grant agreement no 115,565, resources composed of the financial contribution from the European Union's Seventh Framework Program (FP7/2007-2013) and the EFPIA companies' in kind contribution. MT is supported by a Spanish grant from Health Department, Junta de Andalucia (PI/0017/2016) and through the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 806975. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA. EC-M was funded by the Postdoctoral Training Subprogramme Juan de la Cierva-Ministry of Economy and Competitiveness (FJCI_2014_20652). We thank Ralf Lesche for the production of RNASeq data and Marc Torres Ciuro for design support.es_ES
dc.description.abstractPrimary Sjögren’s syndrome (SS) is a systemic autoimmune disease characterized by lymphocytic infiltration and damage of exocrine salivary and lacrimal glands. The etiology of SS is complex with environmental triggers and genetic factors involved. By conducting an integrated multi-omics study, we confirmed a vast coordinated hypomethylation and overexpression effects in IFN-related genes, what is known as the IFN signature. Stratified and conditional analyses suggest a strong interaction between SS-associated HLA genetic variation and the presence of Anti-Ro/SSA autoantibodies in driving the IFN epigenetic signature and determining SS. We report a novel epigenetic signature characterized by increased DNA methylation levels in a large number of genes enriched in pathways such as collagen metabolism and extracellular matrix organization. We identified potential new genetic variants associated with SS that might mediate their risk by altering DNA methylation or gene expression patterns, as well as disease-interacting genetic variants that exhibit regulatory function only in the SS population. Our study sheds new light on the interaction between genetics, autoantibody profiles, DNA methylation and gene expression in SS, and contributes to elucidate the genetic architecture of gene regulation in an autoimmune population.es_ES
dc.description.sponsorshipInnovative Medicines Initiative Joint Undertaking from the European Union's Seventh Framework Program (FP7/2007-2013) 115,565es_ES
dc.description.sponsorshipEFPIA companieses_ES
dc.description.sponsorshipJunta de Andalucia PI/0017/2016es_ES
dc.description.sponsorshipInnovative Medicines Initiative 2 Joint Undertaking 806975 European Union's Horizon 2020 research and innovation programmees_ES
dc.description.sponsorshipEFPIAes_ES
dc.description.sponsorshipPostdoctoral Training Subprogramme Juan de la Cierva-Ministry of Economy and Competitiveness FJCI_2014_20652es_ES
dc.language.isoenges_ES
dc.publisherNaturees_ES
dc.rightsAtribución 3.0 España*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.titleIntegrative epigenomics in Sjögren´s syndrome reveals novel pathways and a strong interaction between the HLA, autoantibodies and the interferon signaturees_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/EC/H2020/806975es_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES
dc.identifier.doi10.1038/s41598-021-01324-0
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersiones_ES


Ficheros en el ítem

[PDF]

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución 3.0 España
Excepto si se señala otra cosa, la licencia del ítem se describe como Atribución 3.0 España